Journal of Pharmaceutical Sciences · 1998 · 91 citations · 18 references
PharmacyPharmaceuticsPharmacologyBioavailabilityDrug DeliveryMucosal Drug DeliveryDrug DispositionGastrointestinal AbsorptionGastrointestinal PharmacologyOral Bioavailability EnhancementOral Mucosal Drug DeliveryTargeted Intestinal DeliveryColon-specific Drug ReleaseColonic Drug ReleaseCyclodextrin-based NanocarriersDrug Transport Across The Intestinal EpitheliumGastrointestinal Drug TransportGastrointestinal ReleaseIntestinal Absorption EnhancementIntestinal Permeation Enhancement
An antiinflammatory drug biphenylylacetic acid (BPAA) as a model drug was selectively conjugated onto one of the primary hydroxyl groups of alpha-, beta-, and gamma-cyclodextrins (CyDs) through an ester or amide linkage, and the in vivo drug release behavior of these prodrugs in rat gastrointestinal tracts after oral administration was investigated. The CyD prodrugs were stable in rat stomach and small intestine and negligibly absorbed from these tracts. Three to six hours after the oral administration, most of the prodrugs had moved to the cecum and colon. The alpha- and gamma-CyD amide prodrugs were hydrolyzed to the maltose conjugate in the cecum and colon, and these prodrugs and the conjugate were negligibly absorbed. On the other hand, the alpha- and gamma-CyD ester prodrugs produced BPAA in the cecum and colon, and BPAA appeared in the blood after 3-6 h. Both beta-CyD amide and ester prodrugs released only small or negligible amounts of the maltose conjugate or BPAA in the cecum and colon, within 24 h, probably due to the low solubility in the biological media. Further, the antiinflammatory effect of the gamma-CyD ester prodrug was evaluated using the model of carageenan-induced acute edema in rat paw and compared with those of BPAA alone and the BPAA/beta-CyD complex prepared by the kneading method in a molar ratio of 1:1. In the case of the beta-CyD complex, a rapid antiinflammatory response was observed, compared to BPAA alone, because the drug is mainly absorbed from the small intestine after a fast dissolution of the complex. In sharp contrast, the gamma-CyD ester prodrug needed a fairly long lag time to exhibit the drug activity, because BPAA is produced after the prodrug had reached the cecum and colon. The present results clearly suggest that the CyD prodrug approach can provide a versatile means for constructions of not only colon-specific delivery systems but also delayed-release system of certain drugs.
18
A New Approach to the Oral Administration of Insulin and Other Peptide Drugs
Murray Saffran, G. Sudesh Kumar, C.M. Savariar et al. · Science · 1986 · 467 citations
Michael Szycher · Journal of Clinical Engineering · 1992 · 152 citations
Oral colon-specific drug delivery
Željka Pavelić, Biljana Nigović, Petra Konosić et al. · 2006 · 110 citations
Fate of β-Cyclodextrin in the Human Intestine
Bernard Flourié, C Molis, Lotfi Achour et al. · Journal of Nutrition · 1993 · 94 citations